Maintenance Therapies

 

Maintenance Therapies

When your cancer treatment ends, your doctor may want you to receive on-going medication or other treatment to help keep your cancer in remission. This is called maintenance therapy, because its goal is to maintain the effectiveness of the original treatment.

Maintenance therapy is used for various cancers, including lymphoma, breast cancer, lung cancer and leukemia, among others. The selection of a maintenance therapy depends upon cancer type, original treatment and other factors. Some maintenance therapies are well-established regimens; others are being tested in clinical trials.

Although you may feel some reassurance that you’re strengthening your prospects for remission by continuing anticancer medication or other maintenance therapy, it may also leave you feeling a bit like you’re in limbo. Your main treatment has ended, but with maintenance therapy, you may feel more like a patient than like someone who is moving forward.  

Take heart from the fact that maintenance therapy is part of your plan to sustain and strengthen your overall health. You may need to manage cancer long-term as part of that plan, but many people have to do the same with other health conditions, including asthma, heart disease, diabetes and high blood pressure.

Be sure to talk with your doctor about your maintenance therapy program so that you understand its schedule and goals. Just as with primary treatment, discuss questions about your medications or any side effects with your doctor as soon as possible. There are good solutions available for many side effects—solutions that will enable you to continue maintenance therapy and benefit from it.                                    

References

“Life After Treatment.” Caring4Cancer magazine. 2006.

Neumann F, Harmsen S, Martin S, et al. “Rituximab Long-term Maintenance Therapy After Autologous Stem Cell Transplantation in Patients with B-cell non-Hodgkin’s Lymphoma.” Annals of Hematology, 2006, Apr. 26, epub ahead of print.

“Glossary: Maintenance Therapy.” Living Beyond Breast Cancer.  http://www.lbbc.org/search.asp?q=maintenance+therapy&final=1&t=GLOSSARY. Accessed 5/16/06

Mattson K, Niiranen A, Ruotsalainen T, et al. “Interferon Maintenance Therapy for Small Cell Lung Cancer: Improvement in Long-Term Survival.” Journal of Interferon & Cytokine Research, 17(2):103-105, Feb. 1997.

Latest Cancer News
Oncotype DX® Predicts Recurrence Risk in Node-negative and Node-positive Breast Cancer Treated with Tamoxifen or Anastrozole

March 10, 2010 — Researchers affiliated with the TransATAC Study have reported that the Oncotype DX® test predicts the risk of distant cancer recurrence in postmenopausal women with early, hormone receptor-positive breast cancer with both node-negative and node-positive disease treated with tamoxifen (Nolvadex®) or anastrozole (Arimidex®). These results were published early online in the Journal of Clinical Oncology on March 8, 2010.

Recent Results of High-dose Proleukin® for Metastatic Renal Cell Carcinoma Reported

March 10, 2010 — Researchers involved in a U.S. multicenter trial (Cytokine Working Group) have reported that high-dose Proleukin® (aldesleukin, interleukin-2, IL-2) results in a higher response rate in patients with metastatic renal cell carcinoma (MRCC) than historically reported. The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, March 5-7, in San Francisco.

Cystoscopy Remains Best Method for Surveillance of Patients with Bladder Cancer

March 10, 2010 — Researchers from the M. D. Anderson Cancer Center have reported that cystoscopy alone remains the most cost-effective method of detecting recurrent superficial bladder cancer. The details of this study were presented at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium March 5-7 in San Francisco.

Select news items provided by Reuters Health